Side-by-side · Research reference
BronchogenvsGDF-8
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BAnimal-StrongHUMAN-REVIEWED23/48 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
GDF-8
TGF-β Superfamily · Negative Muscle Regulator
15–20%Muscle mass gain (MSTN−/−)
Not administered — research target for inhibition
01Mechanism of Action
Parameter
Bronchogen
GDF-8
Primary target
Bronchial epithelial cellsKuzubova 2015
Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026Iglesias 2026
Feedback intact?
—
Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
GDF-8
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
—
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Clinical use
—
None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans
Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.
Inhibition strategies
—
Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)
VLP immunogen (MS2.87-97)
—
Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026
Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026
Dual immunization (MSTN + Activin A)
—
Combined active immunization in GH-deficient miceMansoor 2026
Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026
Gene editing outcomes
—
Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock
Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.
03Metabolic / Fat Loss Evidence
Parameter
Bronchogen
GDF-8
Primary mechanism
—
MSTN loss-of-function reduces fat accumulation independent of muscle mass effects
Human genetic evidence
—
Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026
Animal model outcomes
—
VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026
Adipose-muscle crosstalk
—
MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026
Age-related effects
—
MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation
04Side Effects & Safety
Parameter
Bronchogen
GDF-8
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Genetic null phenotype
—
No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026
Antibody cross-reactivity risk
—
Non-selective inhibitors may block GDF11, affecting cardiac and neural function
VLP immunotherapy safety
—
No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026
Pleiotropic effects (gene editing)
—
MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare
Assay variability
—
Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026
Absolute Contraindications
Bronchogen
—GDF-8
- ·Not applicable — MSTN is not administered as a therapeutic agent
Relative Contraindications
Bronchogen
—GDF-8
- ·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)
05Administration Protocol
Parameter
Bronchogen
GDF-8
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.